Products Targeting Alzheimer's, Duchenne & COVID-19 Among New EU Filings

EU marketing authorization applications have been submitted for a number of new drugs, including Eli Lilly’s donanemab, Italfarmaco's givinostat and Arcturus Therapeutics/CSL’s ARCT-154.

Alzheimer's patient
Donanemab was shown to significantly slow cognitive and functional decline in people with early symptomatic Alzheimer's disease • Source: Shutterstock

Donanemab, Eli Lilly’s investigational treatment for Alzheimer's disease, and Arcturus Therapeutics/CSL’s COVID-19 vaccine candidate, ARCT-154, are among the latest products that the European Medicines Agency has started reviewing for potential pan-EU marketing authorization.

Donanemab is an anti-amyloid therapy for slowing disease progression in patients with early symptomatic Alzheimer’s disease. It is also under...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography